Skip to main content
. 2018 Oct 15;10(10):3243–3253.

Table 4.

Univariate and Multivariate analyses

OS RFS

Univariate analysis Multivariate analysis Univariate analysis Multivariate analysis

N = 95 p-valuea HR p-valueb N = 92 p-valuea HR p-valueb
Age
    ≥ 74/< 74 49/46 0.12 48/44 0.13
Gender
    Male/Female 82/13 0.32 79/13 0.22
Smoking history
    Yes/No 4/91 0.50 3/89 0.81
Stage
    II-IV/I 41/54 0.13 38/54 0.02c 1.97 (1.05-3.71) 0.03c
Lymphatic permeation
    Yes/No 62/31 0.10 29/61 < 0.01c 1.93 (0.94-3.97) 0.07
Vascular invasion
    Yes/No 67/25 0.72 66/23 0.09
Pleural invasion
    Yes/No 37/57 0.02c 2.82 (1.21-3.93) < 0.01c 35/56 < 0.01c 2.23 (1.23-4.04) < 0.01c
Adjuvant therapy
    No/Yes 72/23 0.08 70/22 0.71
PD-L1 expression
    Negative/Positive 25/70 0.25 25/67 0.09
CD8 expression in whole tumor
    Negative/Positive 52/43 0.53 50/42 0.95
CD8 expression in cancer nest
    Negative/Positive 71/24 0.67 69/23 0.61
CD8 expression in cancer stroma
    Negative/Positive 45/50 0.44 43/49 0.82
CD4 expression in whole tumor
    Negative/Positive 19/76 0.43 19/73 0.38
CD4 expression in cancer nest
    Negative/Positive 80/15 0.69 77/15 0.68
CD4 expression in cancer stroma
    Negative/Positive 17/78 0.14 17/75 0.03c 0.31 (0.11-0.82) 0.02c
Foxp3 expression
    Negative/Positive 52/43 0.01c 1.97 (1.06-3.68) 0.03c 50/42 < 0.01c 1.97 (1.05-3.71) 0.04c
a

Log-rank test;

b

Cox proportional hazard model;

c

denotes significance.